- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02595853
Efficacy of a Novel Hemostatic Powder in GI Bleeding (GRAPHE)
September 8, 2021 updated by: Nantes University Hospital
A Novel Hemostatic Powder for the Endoscopic Treatment of Gastrointestinal Bleeding: Evaluation of Efficacy, Feasibility and Rebleeding Predictive Factors Results From a Multicenter Prospective Study Performed in Routine Practice
Hemospray™ is a new endoscopic hemostatic powder.
Aims of this multicenter prospective study is to determine effectiveness of Hemospray™ on short and medium term in different clinical situations, predictive factors of rebleeding after Hemospray™ application, and feasibility of the application of hemostatic powder in routine clinical practice studying in a large sample of patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
200
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Angers, France, 49933
- Angers University Hospital
-
Besançon, France, 25030
- Besançon University Hospital
-
Bordeaux, France, 33076
- Bordeuax University Hospital
-
Lille, France, 59037
- Lille University Hospital
-
Limoges, France, 87042
- Limoges university hospital
-
Marseille, France, 13005
- La Conception University Hospital
-
Marseille, France, 13005
- La Timone University Hospital
-
Nantes, France, 44093
- Nantes University Hospital
-
Nîmes, France, 30029
- Nîmes University Hospital
-
Paris, France, 75000
- Cochin University Hospital
-
Paris, France, 75000
- Georges Pompidou University Hospital (AP-HP)
-
Paris, France, 75000
- Henri Mondor University Hospital (AP-HP)
-
Paris, France, 75000
- Lariboisière University Hospital (AP-HP)
-
Rouen, France, 76031
- ROUEN university hospital
-
Saint-Brieuc, France, 22000
- Saint-Brieuc University Hospital
-
Toulouse, France, 31000
- Clinique des Cèdres
-
Tours, France, 37044
- Tours university Hospital
-
Vichy, France, 03200
- Vichy Hospital
-
-
-
-
-
Monaco, Monaco, 98012
- Monaco University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
All adult patients who received hemostatic powder for upper GI bleeding will be included in the study.
Pregnant and adult under guardianship will be excluded.
Description
Inclusion Criteria:
- Male or female aged 18 and over who need the use of Hemospray® under their care in an emergency.
- Upper gastrointestinal hemorrhage.
- Patients who received the information note of the study and agreeing to participate (non-oral opposition gathered in the patient's medical record)
Non Inclusion Criteria:
- Patient under guardianship, curatorship.
- Pregnant woman.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of immediate cessation of bleeding observed in first-line per procedure or after failure of normal hemostasis techniques.
Time Frame: 30 days
|
Percentage of immediate cessation of bleeding observed in first-line per procedure or after failure of normal hemostasis techniques.
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rebleeding rate at days 8 and 30, defined as the percentage of patients with >2g/dL hemoglobin AND/OR exteriorization of hematemesis AND/OR exteriorization of melena
Time Frame: 30 days
|
Rebleeding rate at days 8 and 30, defined as the percentage of patients with >2g/dL hemoglobin AND/OR exteriorization of hematemesis AND/OR exteriorization of melena
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2014
Primary Completion (Actual)
January 1, 2015
Study Completion (Actual)
January 1, 2015
Study Registration Dates
First Submitted
October 29, 2015
First Submitted That Met QC Criteria
November 2, 2015
First Posted (Estimate)
November 4, 2015
Study Record Updates
Last Update Posted (Actual)
September 10, 2021
Last Update Submitted That Met QC Criteria
September 8, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC14_0077
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Bleeding
-
Waihong ChungUnknownMetoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy (MANPURSE)Upper Gastrointestinal Bleeding | Gastro Intestinal BleedingUnited States
-
Ottawa Hospital Research InstituteRecruitingGastroIntestinal Bleeding | Anticoagulant-induced BleedingCanada
-
Boston Children's HospitalBaylor College of Medicine; Children's Hospital of Philadelphia; Ann & Robert... and other collaboratorsRecruitingUpper Gastrointestinal Bleeding | Gastro Intestinal BleedingUnited States
-
National University of SingaporeRecruitingGastroIntestinal BleedingSingapore
-
Next Biomedical Co., Ltd.CompletedGastroIntestinal BleedingKorea, Republic of
-
University Hospital FreiburgRecruitingGastroIntestinal BleedingGermany
-
University Hospital AugsburgRecruitingUpper Gastrointestinal BleedingGermany
-
EnteraSense LimitedCompletedUpper Gastrointestinal BleedingCzechia
-
McGill University Health Centre/Research Institute...ASGECompletedMALIGNANT GASTROINTESTINAL BLEEDINGCanada
Clinical Trials on Non interventional study
-
Universitätsklinikum Hamburg-EppendorfSandozUnknownPsoriasisDenmark, Spain, Germany, Poland
-
University Hospital, RouenRecruitingDyspepsia | Irritable Bowel Syndrome | Functional Constipation | Faecal IncontinenceFrance
-
Mayo ClinicRecruitingOropharyngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Oropharyngeal (p16-Negative)... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute...RecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphatic System NeoplasmUnited States
-
Mayo ClinicRecruitingStage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Stage IIIA Bladder Cancer AJCC v8 | Stage II Bladder Cancer AJCC v8United States
-
Mayo ClinicRecruitingClear Cell Renal Cell Carcinoma | Urothelial Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Kidney Oncocytoma | Clear Cell Papillary Renal TumorUnited States
-
Mayo ClinicRecruitingProstate CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI); National Institute for Biomedical Imaging...RecruitingProstate NeoplasmUnited States
-
University of WashingtonNational Cancer Institute (NCI)RecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal CarcinomaUnited States
-
Mayo ClinicRecruitingBreast CarcinomaUnited States